This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-16 and is reviewed periodically as new material appears.
Quality testing of collagen peptides relies on several analytical methods. Molecular weight distribution is commonly measured by size-exclusion chromatography, sometimes paired with multi-angle light scattering. Amino acid composition is determined by ion-exchange chromatography or reversed-phase high-performance liquid chromatography after acid hydrolysis, while protein content is estimated by Kjeldahl or Dumas nitrogen analysis. Moisture, ash, and heavy metals are checked against specification limits. These tests help ensure consistency and detect adulteration with other proteins.
Regulatory treatment of collagen peptides varies by country and intended use. In the United States, they are typically marketed as dietary supplements or food ingredients, and certain uses may be generally recognized as safe (GRAS) through self-affirmation or notification. In the European Union, collagen peptides from approved animal sources are considered food, not novel foods, if they have a history of consumption. Health claims linking collagen peptides to joint or skin benefits are not approved in the US or EU. Labeling must list the animal source and may state the protein content.
Manufacturing collagen peptides begins with collagen-rich raw materials such as bovine hide, porcine skin, fish scales, or poultry cartilage, which undergo washing, size reduction, and pretreatment to remove non-collagen proteins and fats. Extraction may use acid, alkali, or heat. Hydrolysis then breaks the collagen into smaller peptides, often with enzymes such as pepsin, papain, or alcalase. Process conditions of time, temperature, pH, and enzyme dose determine the final molecular weight distribution. After hydrolysis, the solution is filtered, concentrated, and dried into powder.
Molecular weight distribution is a key characteristic of collagen peptide preparations and influences solubility, viscosity, and absorption behavior. Low-molecular-weight fractions, often below 3,000 daltons, dissolve readily and may pass through intestinal barriers more efficiently than larger fragments. Higher-molecular-weight fractions can form viscous solutions and may retain some gel-like properties. Analytical techniques such as size exclusion chromatography reveal a broad distribution rather than a single peak. The average molecular weight is frequently reported, but the range and proportions of different sizes vary by manufacturer and process.
Collagen peptides are short chains of amino acids derived from collagen, the main structural protein in connective tissues. They are produced by hydrolysis, which breaks the triple-helical structure of native collagen into smaller fragments. The resulting peptides typically have molecular weights between 2,000 and 10,000 daltons, though commercial preparations vary. Unlike intact collagen, these peptides are water-soluble and do not form gels at room temperature. The term "collagen peptide" often refers to a mixture of fragments rather than a single defined molecule.
Amino acid composition of collagen peptides reflects that of the parent collagen, with glycine, proline, and hydroxyproline being particularly abundant. Glycine appears at nearly every third residue in the repeating sequence Gly-X-Y, where X and Y are often proline or hydroxyproline. This pattern is partly retained in short peptides, though hydrolysis can cleave at various sites. Hydroxyproline is uncommon in most other proteins and serves as a marker for collagen-derived material. The presence of these amino acids contributes to the unique properties of collagen peptides, including their resistance to certain proteases.
| Property | Value | Notes |
|---|---|---|
| Protein content | ≥90% (dry basis) | Determined by Kjeldahl or Dumas; varies by grade |
| Moisture | ≤10% | Higher moisture reduces shelf life and promotes clumping |
| Heavy metals | Lead ≤2 mg/kg; arsenic ≤1 mg/kg | Limits vary by jurisdiction; tested by ICP-MS |
| Microbial limits | Total aerobic count ≤10^4 CFU/g | Typical specification for food-grade powders |
| Labeling | Hydrolyzed collagen or collagen peptides | Source animal must be declared in many markets |
Storage and handling of collagen peptides require protection from moisture, heat, and light. The powders are hygroscopic and can absorb water from the air, leading to clumping or microbial growth. Typical storage conditions are a cool, dry place at room temperature or below, in tightly sealed containers. Some manufacturers recommend refrigeration for long-term stability. Solutions prepared from the powder are less stable and should be used promptly or preserved according to validated protocols.
Production of collagen peptides begins with raw materials such as bovine hide, porcine skin, fish scales, or poultry cartilage. The collagen is extracted, often with acid or alkaline treatment, and then subjected to hydrolysis using enzymes like pepsin or alcalase, or chemical agents. Enzymatic hydrolysis is favored for its mild conditions and controllability. The resulting mixture is filtered, concentrated, and dried to yield a powder. Process parameters such as temperature, pH, and enzyme-to-substrate ratio determine the molecular weight profile and yield.
Collagen peptides are distinguished from gelatin by their lower average molecular weight and better solubility in cold water. Gelatin forms gels upon cooling, while collagen peptides typically do not. Molecular weight distributions for commercial collagen peptides often range from about 2 to 20 kilodaltons, though exact profiles vary by manufacturer and process. Products may be sold as powders, capsules, or liquids. The term "collagen hydrolysate" is frequently used as a synonym, although labeling conventions differ across regions.
Collagen is a structural protein found in connective tissues of animals, and collagen peptides are short amino acid chains produced by hydrolyzing native collagen into smaller fragments. The hydrolysis process typically uses enzymes or acids under controlled conditions. Commercial collagen peptides often come from bovine hide, porcine skin, or fish scales. The resulting material is water-soluble and differs from intact collagen in molecular size and behavior. The term 'collagen peptide' generally refers to a mixture of peptide chains rather than a single defined molecule.
Production begins with cleaning and mincing raw collagen-rich tissues. The material undergoes pretreatment to remove non-collagenous components, followed by hydrolysis using enzymes such as pepsin or alcalase, or by acid or alkaline treatment. Reaction time, temperature, and pH influence the average molecular weight of the resulting peptides. After hydrolysis, the mixture is filtered, concentrated, and dried, often by spray drying. The final product is a powder with a characteristic amino acid profile rich in glycine, proline, and hydroxyproline.
Additional tests assess moisture, ash, and nitrogen content to confirm overall composition and processing consistency. Heavy metal analysis, including lead, arsenic, cadmium, and mercury, is performed to ensure limits are not exceeded. Microbial testing checks for total aerobic counts, yeast, mold, and specific pathogens such as Salmonella and Escherichia coli. These safety parameters are often required by regulations for food or dietary supplement ingredients. Results are compared against internal or pharmacopeial specifications, which may differ between jurisdictions.
One challenge in collagen peptide analysis is the absence of a single reference standard that covers all possible molecular weight fractions. Products from different sources or hydrolysis conditions yield different peptide profiles, complicating direct comparisons. Some laboratories use gelatin or a defined peptide mixture as a calibration standard, but this approach has limitations. Additionally, the term "collagen peptide" itself lacks a universally accepted molecular weight cutoff. Ongoing discussions aim to establish more consistent definitions and testing protocols for regulatory and research purposes.
Quality control of collagen peptides relies on methods that characterize molecular weight distribution, amino acid composition, and purity. Size exclusion chromatography (SEC) is commonly used to estimate the molecular weight profile of peptide mixtures. High-performance liquid chromatography (HPLC) can separate and quantify individual peptide fractions. Mass spectrometry provides detailed information on peptide sequences and modifications. These techniques help verify that a product meets declared specifications, though standardization across laboratories remains limited.
=== Constipation === Opioid-induced constipation (OIC) develops in 90 to 95% of people taking opioids long-term. Since tolerance to this problem does not generally develop, most people on long-term opioids need to take a laxative and/or enemas. Treatment of OIC is successional and dependent on severity. The first mode of treatment is non-pharmacological, and includes lifestyle modifications like increasing dietary fiber, fluid intake (around 1.5 L (51 US fl oz) per day), and physical activity. If non-pharmacological measures are ineffective, laxatives, including stool softeners (e.g., polyethylene glycol), bulk-forming laxatives (e.g., fiber supplements), stimulant laxatives (e.g., bisacodyl, senna), and/or enemas, may be used. A common laxative regimen for OIC is the combination of docusate and bisacodyl. Osmotic laxatives, including lactulose, polyethylene glycol, and milk of magnesia (magnesium hydroxide), as well as mineral oil (a lubricant laxative), are also commonly used for OIC. If laxatives are insufficiently effective (which is often the case), opioid formulations or regimens that include a peripherally-selective opioid antagonist, such as methylnaltrexone bromide, naloxegol, alvimopan, or naloxone (as in oxycodone/naloxone), may be tried. A 2018 (updated in 2022) Cochrane review found that the evidence was moderate for alvimopan, naloxone, or methylnaltrexone bromide but with increased risk of adverse events. Naloxone by mouth appears to be the most effective.
=== Legal status === Cipaglucosidase alfa is available in the UK, since June 2021, under the Early Access to Medicines Scheme. In December 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Pombiliti, intended for the treatment of glycogen storage disease type II (Pompe disease). The applicant for this medicinal product is Amicus Therapeutics Europe Limited. Cipaglucosidase alfa was approved for medical use in the European Union in March 2023.
Anti-trans actors employ various strategies in their spread of misinformation around transgender health care by inventing pseudoscientific concepts and attacking professionals and organizations that provide gender affirming care, trying to frame gender-affirming care as "dangerous" or "experimental" or claims that a majority of transgender youth will detransition, something scientists have refuted and named the desistance myth, or can be cured using conversion therapy.
Creutzfeldt–Jakob disease (CJD) is an incurable, terminal, neurodegenerative disease belonging to the transmissible spongiform encephalopathy (TSE) group, also known as prion diseases. Early symptoms include memory problems, behavioral changes, poor coordination, visual disturbances and auditory disturbances. Later symptoms include dementia, involuntary movements, blindness, deafness, weakness, and coma. About 70% of patients die within a year of diagnosis. The condition was first described in 1920. The name "Creutzfeldt–Jakob disease" was introduced by Walther Spielmeyer in 1922, after the German neurologists Hans Gerhard Creutzfeldt and Alfons Maria Jakob. CJD is caused by a prion, an infectious, abnormally folded variant of a protein called the prion protein. About 85% of cases of CJD occur for unknown reasons ('sporadic CJD'), while about 10–15% of cases are inherited in an autosomal dominant manner. In rare instances, exposure to brain or spinal tissue from an infected person has resulted in transmission of disease, and a variant form of CJD was caused by exposure to meat from cows with bovine spongiform encephalopathy ("mad cow disease"). There is no evidence that sporadic CJD can spread among people via normal contact or blood transfusions, although this is possible in variant Creutzfeldt–Jakob disease. Diagnosis of CJD involves ruling out other potential causes. An electroencephalogram, spinal tap, or magnetic resonance imaging (MRI) may support the diagnosis.
Acetorphine is a potent opioid analgesic, up to 8700 times stronger than morphine by weight. It is a derivative of the more well-known opioid etorphine, which is used as a very potent veterinary painkiller and anesthetic medication, primarily for the sedation of large animals such as elephants, giraffes and rhinos. Acetorphine was developed in 1966 by the Reckitt research group that developed etorphine. Acetorphine was developed for the same purpose as etorphine itself, namely as a strong tranquilizer for use in immobilizing large animals in veterinary medicine. Despite showing some advantages over etorphine, for instance producing less toxic side effects in giraffes, acetorphine was never widely adopted for veterinary use, and etorphine (along with other tranquilizers such as carfentanil and azaperone) remains the drug of choice in this application.
Sources: en.wikipedia.org
=== Generic names === Metenolone is the generic name of the drug and its INNTooltip International Nonproprietary Name, while methenolone is its BANTooltip British Approved Name. It has also been referred to as methylandrostenolone. This synonym should not be confused with methandrostenolone, which is another name for a different AAS known as metandienone.
President Biden signs his first executive orders reversing several Trump administration actions, including rejoining the Paris Agreement and the World Health Organization, repealing the 2017 travel bans, ending funding for the Mexico–United States border wall, and revoking the permit for the Keystone XL pipeline. January 21 – The Food and Drug Administration (FDA) approves Cabenuva as a complete regimen for the treatment of HIV/AIDS. January 22 – Recreational cannabis sales begin in Arizona. January 24 COVID-19 pandemic: Nationwide confirmed COVID-19 cases surpass 25 million. The Tampa Bay Buccaneers advance to Super Bowl LV after a 31–26 victory against the Green Bay Packers, the first time an NFL team will play the Super Bowl on their home field. January 25 President Biden repeals the Trump administration's ban on transgender personnel in the military. COVID-19 pandemic: Minnesota reports the first national case of the Lineage P.1 variant of SARS-CoV-2. Dominion Voting Systems sues former New York City mayor Rudy Giuliani, accusing him of defamation during the 2020 presidential election. January 26 COVID-19 pandemic: The Biden administration announces it will purchase 200 million COVID-19 vaccine doses from Pfizer/BioNTech and Moderna, in addition to the prior order of 400 million. January 27 The U.S. Army announces new personal grooming and appearance standards, relaxing rules regarding makeup and jewelry and allowing for more diverse hairstyles.
Reversed-phase HPLC (RP-HPLC) is the most widespread mode of chromatography. It has a non-polar stationary phase and an aqueous, moderately polar mobile phase. RP-HPLC is so commonly used among the biologists and life science users, that it is often referred to as simply "HPLC". The pharmaceutical industry also regularly employs RP-HPLC to qualify drugs before their release. In the reversed phase methods, the substances are retained in the system the more hydrophobic they are. For the retention of organic materials, the stationary phases, are consisted mainly of porous granules of silica gel packed in the column. In shape, they are usually spheres of varying diameters (sub-2, 3, 5, 7, 10 μm), varying pore diameters (60, 100, 150, 300 Å). On their surface are chemically bonded straight chain alkyl ligands, such as C3, C4, C8, C18. The number counts the carbon atoms in a ligand. For example, a C3 ligand is a propyl. The longer the hydrocarbon ligand on the stationary phase, the longer the sample components can be retained. Most of the current methods of separation of biomedical materials use C18 stationary phase, sometimes called by a trade names such as ODS (octadecylsilane) or RP-18 (Reversed Phase 18). To make such stationary phases, one treat the surface of silica gel particles with RMe2SiCl, where R is a straight chain alkyl group such as C18H37 or C8H17. To separate aromatic compounds, or in general compounds with many pi bonds, the stationary phase can have phenyl surface ligands. At pH < 2, the bond between the ligand and the silica gel may dissolve.
=== Detection in body fluids === The most commonly employed human physiological specimen for detecting AAS usage is urine, although both blood and hair have been investigated for this purpose. The AAS, whether of endogenous or exogenous origin, are subject to extensive hepatic biotransformation by a variety of enzymatic pathways. The primary urinary metabolites may be detectable for up to 30 days after the last use, depending on the specific agent, dose and route of administration. A number of the drugs have common metabolic pathways, and their excretion profiles may overlap those of the endogenous steroids, making interpretation of testing results a significant challenge to the analytical chemist. Methods for detection of the substances or their excretion products in urine specimens usually involve gas chromatography–mass spectrometry or liquid chromatography-mass spectrometry.
High mass accuracy: The mass deviation of the input spectra should be within 20 ppm. Mass spectrometry devices such as TOF, Orbitrap and FT-ICR usually provide data with high mass accuracy, as do coupled devices such as Q-TOF, IT-TOF or IT-Orbitrap. Spectra measured with a quadrupole or linear trap do not provide the required accuracy for data analysis with SIRIUS. Rich fragmentation spectra: It is not possible to deduce the structure or even the molecular formula from an MS2 spectrum that contains almost no peaks. Prior noise filtering of the spectra is not necessary and not favorable. SIRIUS considers up to 60 peaks in the fragmentation spectrum and decides for itself which of these peaks are regarded as noise. Centroided MS data: SIRIUS does not contain routines for peak picking from profile-mode spectra. msConvert in ProteoWizard can be used to convert to centroided data. Additionally, there are several tools specialized for the preprocessing task, such as OpenMS, MZmine or XCMS. OpenMS and MZmine 3 both provide export functions tailored to the needs for SIRIUS. Different common MS file formats, such as .csv, .ms or .mgf files, can be imported to SIRIUS. SIRIUS can import full LC-MS-runs (.mzML) or single compounds. At present, SIRIUS only handles single-charged compounds.
Sources: en.wikipedia.org
Size-exclusion chromatography is the standard method, often with refractive index or ultraviolet detection. Calibration uses known protein standards. SDS-PAGE can provide a rough range but is less precise.
No. In most countries they are regulated as food ingredients or dietary supplements. They cannot carry claims to treat or prevent disease.
Dry powder should be kept in sealed containers at ambient temperature, away from moisture and direct sunlight. High humidity can cause clumping and microbial growth. Liquid formulations may require refrigeration.
No, collagen peptides are shorter fragments produced by hydrolysis, while native collagen retains its triple-helical structure. The hydrolysis process breaks the protein into smaller, water-soluble chains. This difference affects solubility, gel formation, and how the material behaves in formulations.